UPXI · Upexi, Inc.

Current Thesis

Upexi’s Solana-discount recovery depends on the annual report establishing positive net assets and Nasdaq confirming a bid-price cure; gross coin value alone does not establish the case.

The Block’s September 7, 2026 treasury snapshot reported 2,174,583 SOL, the Solana network’s token, worth $228.57 million against $70.1 million of equity market capitalisation, with a stated multiple of 0.31×. That comparison measures equity against gross token value. It does not establish the amount attributable to common shareholders after liabilities.

The material correction to the September 7 interpretation concerns those liabilities: Upexi’s March 31, 2026 balance sheet reported $181,031,073 of convertible notes payable and a $51,918,186 stockholders’ deficit. Those historical figures cannot be combined with September token prices to manufacture a current net asset value. Fiscal third-quarter Form 10-Q.

For the original premium-funded treasury expansion story, the narrative is dead — an inference dated by the July 30, 2026 Nasdaq deficiency notice and the September 4 shares standing 86.1% below their adjusted 52-week high. The narrower recovery proposition remains unproven. Its success requires audited positive stockholders’ equity and written bid-price compliance confirmation before a weekly close below $1.00 invalidates the price structure.

Bullish and bearish views on Upexi, Inc.

The model's bull view on Upexi, Inc. (UPXI), in brief: Digital assets produce reported revenue. The bear view: Gross assets overstate equity backing. Beyond convertible notes, the March 31, 2026 balance sheet reported $57,295,723 of short-term treasury debt. A comparison with gross SOL value omits these claims. Fiscal third-quarter Form 10-Q. Treasury counts require reconciliation. The… Both cases follow in full.

Bull Case

• Digital assets produce reported revenue. Upexi recorded $3,506,432 of digital-asset revenue for the quarter ended March 31, 2026. This establishes an income contribution alongside token-price exposure. Fiscal third-quarter Form 10-Q.
• A price-based compliance path remains. The July 31, 2026 filing gives Upexi until January 26, 2027 to restore its closing bid to at least $1.00 for a minimum of ten consecutive business days; Nasdaq can require longer. Bid-price deficiency disclosure.

Bear Case

• Gross assets overstate equity backing. Beyond convertible notes, the March 31, 2026 balance sheet reported $57,295,723 of short-term treasury debt. A comparison with gross SOL value omits these claims. Fiscal third-quarter Form 10-Q.
• Treasury counts require reconciliation. The March 31, 2026 filing reported approximately 1,383,079 liquid SOL and 978,852 locked SOL. The September 7 tracker’s 2,174,583 SOL figure is a differently dated observation; repeated tracker readings cannot establish that accumulation stopped. Fiscal third-quarter Form 10-Q.
• Recent financing complicates the comparison. Upexi announced pricing of an approximately $19.5 million private placement on June 22, 2026. The annual report must reconcile financing and subsequent events before the September tracker comparison can support a current valuation conclusion. Company investor-relations announcements.

Setup & Price Structure

The adjusted market close was $1.07 on September 4, 2026. The supplied daily-bar record showed a three-month price increase of 12.6%, a 14-day relative strength index of 65.8, and an adjusted 52-week high of $7.70. These measurements describe a rebound within a substantial decline; they do not establish a completed base.

The $1.00 research boundary is the minimum-bid threshold disclosed on July 31, 2026. A weekly close below $1.00 would invalidate this recovery case. An adjusted transaction close is distinct from Nasdaq’s closing-bid test, and the September 4 observation cannot establish a qualifying streak. Nasdaq notice disclosure.

The June 22 financing announcement is observable share-supply evidence. Retail-flow, short-interest and moving-average-distance measurements are absent from the September 8 evidence set, so crowding cannot be established.

Catalyst Calendar (next 30 days)

• 2026-09-28 — expected annual-report checkpoint. This remains the anticipated fiscal 2026 filing checkpoint, not a company-confirmed earnings appointment. As checked September 8, 2026, Upexi’s financial-results page still listed the March quarter as its latest results. The report is the test of audited net assets, treasury composition and financing; continued negative stockholders’ equity would defeat the fundamental recovery case. Company financial-results page.

No company-confirmed earnings-call date inside the next 30 days was identified in the September 8 review. September 28 is therefore a provisional disclosure checkpoint; a report not appearing that day would leave the financial test unresolved, without independently establishing a listing violation.

What Would Change Our Mind

Loss of the disclosed minimum-bid threshold would break the recovery structure: a weekly close below $1.00 is the price invalidation. The fundamental case would also fail if the fiscal 2026 annual report continued to show negative stockholders’ equity.

Conversely, audited positive stockholders’ equity and written Nasdaq bid-price compliance confirmation would satisfy the stated recovery case if both arrived before the price invalidation. The July 31 notice makes clear that a qualifying bid streak is subject to Nasdaq’s discretion; a single close above the threshold cannot substitute for confirmation. Company deficiency disclosure.

Correlation Notes

FrontierPicks’ September 6, 2026 review classified the Crypto exchanges & financials group as accelerating, following a maturing classification on August 30. That is group-level narrative evidence, not a measurement of demand for Upexi.

The Block snapshots dated September 4 and September 7 are too small a sample to support an equity–SOL correlation claim, particularly without synchronised equity valuations. The company’s March 31 debt disclosure also prevents treating gross token appreciation as equivalent to improvement in common-shareholder value.